Shanghai Medicilon (SHSE:688202) Cash Flow for Dividends: ¥-7 Mil (TTM As of Mar. 2026)


SHSE:688202 Shanghai Medicilon Inc SHSE:688202
71 GF Score
Price ¥78.50
GF Value ¥45.98
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Medicilon Cash Flow for Dividends?

Shanghai Medicilon SHSE:688202 +1.16% 71 Cash Flow for Dividends is ¥-7 Mil as of Mar. 2026. GuruFocus rates SHSE:688202 with a GF Score™ of 71/100 and a GF Value™ of ¥45.98 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shanghai Medicilon's cash flow for dividends for the three months ended in Mar. 2026 was ¥-1 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-7 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Shanghai Medicilon's quarterly payment of dividends increased from Sep. 2025 (¥-2 Mil) to Dec. 2025 (¥-2 Mil) but then declined from Dec. 2025 (¥-2 Mil) to Mar. 2026 (¥-1 Mil).

Shanghai Medicilon's annual payment of dividends declined from Dec. 2023 (¥-42 Mil) to Dec. 2024 (¥-7 Mil) but then increased from Dec. 2024 (¥-7 Mil) to Dec. 2025 (¥-7 Mil).

Shanghai Medicilon Cash Flow for Dividends Related Terms

Shanghai Medicilon Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Shanghai Medicilon's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Medicilon Cash Flow for Dividends Chart

Shanghai Medicilon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.06 -87.33 -42.15 -6.98 -7.42

Shanghai Medicilon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.75 -2.35 -1.53 -1.80 -0.89
SHSE:688202
71GF Score
Shanghai Medicilon Inc SHSE:688202
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Medicilon Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ¥-7 Mil mean?
Shanghai Medicilon (SHSE:688202) has a Cash Flow for Dividends of ¥-7 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Shanghai Medicilon and its competitors.
Is Shanghai Medicilon's Cash Flow for Dividends too high?
Shanghai Medicilon's current Cash Flow for Dividends is ¥-7 Mil. Overall, Shanghai Medicilon has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's Cash Flow for Dividends compare to VRTX and REGN?
Shanghai Medicilon's Cash Flow for Dividends of ¥-7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Shanghai Medicilon and its competitors. Shanghai Medicilon's current Cash Flow for Dividends is ¥-7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.98, compared to a current price of ¥78.50 — trading 70.7% above its estimated fair value. The current Cash Flow for Dividends is ¥-7 Mil. Shanghai Medicilon's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current Cash Flow for Dividends is ¥-7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued. The current stock price of ¥78.50 is trading 70.7% above its estimated GF Value™ of ¥45.98. GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.

Key valuation signals for SHSE:688202:

  • Cash Flow for Dividends: ¥-7 Mil
  • GF Value™: ¥45.98 vs. price of ¥78.50 (70.7% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Medicilon Business Description

Address Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
71GF Score

Get the complete analysis for SHSE:688202

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥78.50
Price
¥45.98
GF Value